$RGNT REGENTIS BIOMATERIALS Market cap : 35 M They are developing GelrinC (biomimetic hydrogel designed for cartilage repai) Fully approved for Europe. Currently in the marketing process. Training trauma surgeons at the prestigious Humanitas-Milan hospital. Pending FDA approval in the USA. Phase III The primary advantage of GelrinC compared to traditional cartilage repair treatments is its ability to regenerate high-quality, natural tissue rather than simply patching the area with inferior scar tissue. Here are the key advantages: Perfect Conformance: Because it is applied as a liquid and cures in situ (within the body), it perfectly fills the specific shape of any cartilage defect. This provides a significant advantage over solid implants or bone plugs, which struggle to match irregular injury sites. Hyaline Cartilage Regeneration: Many traditional treatments result in the formation of "fibrocartilage," which is essentially scar tissue—it is stiffer and wears out faster. GelrinC is engineered to stimulate the body to produce hyaline cartilage, which is the healthy, elastic, and durable tissue that naturally cushions joints. Biodegradability: The hydrogel acts as a temporary "scaffold." Once it facilitates the growth of the patient's own new cartilage, the material degrades safely and is naturally cleared by the body, leaving no foreign material behind. Minimally Invasive: It is designed for application via arthroscopic surgery. This reduces trauma to the patient, typically leading to a faster recovery compared to more invasive open-joint surgeries. Quality management Dr. Ehud Geller, the CEO and Executive Chairman of Regentis Biomaterials, has a career spanning over 30 years of executive and operational experience in the healthcare, biotechnology, and pharmaceutical sectors, both in the United States and Israel. Below is a summary of his professional background: Executive Leadership Regentis Biomaterials: In addition to his current role as CEO and Executive Chairman, he has been central to the company’s strategic direction and the commercial development of its core technology. Teva Pharmaceutical Industries: He served as President of the Pharmaceutical Division and Executive Vice President of the Group. During his tenure, he led Teva’s strategic entry into the U.S. market and oversaw the integration of Ikapharm Ltd. Interpharm Laboratories, Ltd.: As President and CEO, he managed the company's growth from an early-stage startup to a significant entity with a market capitalization exceeding $380 million by 1991. Medica Venture Partners: He is a founding partner and managing director of this venture capital firm. Established in 1995, the firm has been a pioneer in Israeli healthcare investments, focusing on the development of innovative medical devices. Conclusion: It rose sharply yesterday, but with full approval for the European market and Phase III trials in the USA. , in a market with enormous potential like cartilage injuries, I think it's a company to seriously consider. (This is not a purchase recommendation. There are undisclosed risks.)

🦵 $RGNT — The knee cartilage repair nobody knew existed. Until today. Regentis Biomaterials exploded 136% today. Before you chase the spike — here's what's actually behind it. The product: GelrinC® → Off-the-shelf hydrogel implant for knee cartilage repair → 10-minute single-step procedure → CE Mark approved in Europe ✅ → 100% greater pain improvement vs standard microfracture → MRI-confirmed cartilage regeneration up to 4 years The market nobody has solved: → 470,000 annual knee cartilage repair cases in the U.S. → Zero approved off-the-shelf solution available today → $3 billion market. Wide open. The catalyst pipeline: → Q3 2026: European surgeon training begins in Milan 🇮🇹 → 2026: Commercial launch in Europe → 2026-2027: Phase III FDA trial completion (50% enrolled) → 2027: FDA submission The CEO: Ehud Geller, PhD — former President & CEO of Interpharm Laboratories, former EVP at Teva Group. Not a turnaround specialist. A pharma builder. The honest caveat: Today's 136% was pure momentum on low float — spike to $7.33 premarket, back to $3 by afternoon. Book value: $0.92 per share. Current price trades well above fundamentals. But the technology pipeline is real. The market opportunity is real. And the catalysts are coming. Watch the story, not just today's chart. Not financial advice. Do your own research. $RGNT 🦵 Somebody had to say it. 🐥 #RGNT #Biotech #RegenerativeMedicine #GelrinC #Orthopedics

Make it in the Emirates 2026 closes today. What the UAE has built isn't an event it's a national platform where manufacturers, regulators, financiers, & authorities meet on the same floor. Honored that CS Interpharm was a part of this story. 🇦🇪 #ProudToMakeItInTheEmirates #miite

Yesterday's Recap: $CSDX CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH otcmarkets.com/stock/CSDX/ne…

UPDATE :NEWS [ $CSDX : Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH $MSFT $NVDA $META $GOOGL $AMZN $LLY $AAPL $TSLA $AVGO $NFLX ichigodoran.blogspot.com/202…

$CSDX Auditor Appointment: $CSDX appoints Shah Teelani & Associates, a Dubai-based PCAOB-registered audit firm, to consolidate all 2025 financial statements for CS Group and its international subsidiaries CS Interpharm GT LLC and CS Diagnostics Pharma GmbH.#CSDX #OTCMarkets #MedTech #CorporateGovernance #FinancialTransparency otcmarkets.com/stock/CSDX/ne…

$CSDX CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH otcmarkets.com/stock/CSDX/ne…

$CSDX News! CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH finance.yahoo.com/news/cs-gr…

$CSDX CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH globenewswire.com/news-relea…

$CSDX 🚨 insider buys - 42,560,096 - CS Interpharm General Trading Co. LLC 104,507,800 - CS Diagnostics Pharma GmbH - 196,430,396 13g 13,392,434.00 - Thomas Graus 13,596,680.00 - Antonio Santoli - 26,989,114 223,419,510 TOTAL OWNED 15,266,967 HELD DTC - 238,686,477 TOTAL OUTSTANDING - 249,992,200 total left 11,305,723---lets lock the float investors! @CSDX_CSDCorp

$CSDX 🚨 After those insider buys we have to be getting close to something here... just a thought... insider buys - 49,362,500 - CS Interpharm LLC 42,560,096 - CS Interpharm General Trading Co. LLC 104,507,800 - CS Diagnostics Pharma GmbH - 196,430,396 13g 13,392,434.00 - Thomas Graus 13,596,680.00 - Antonio Santoli - 26,989,114 223,419,510 TOTAL OWNED 15,266,967 HELD DTC - 238,686,477 TOTAL OUTSTANDING - 249,992,200 left 11,305,723 @CSDX_CSDCorp 👀

$CSDX another Strong Fundamental OTC! CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDX's Path to Consolidated Financial Reporting

💡 Investor Insight: $CSDX CS Diagnostics Corp. (OTCQB: $CSDX) just achieved a major corporate milestone in its roadmap toward financial consolidation and NASDAQ readiness. Its key affiliates — CS Interpharm and CS Diagnostics Pharma — have converted all Series B Preferred Stock into common shares, unifying the CS Group under a single equity class. Here’s why this move matters for shareholders 👇 1️⃣ Cleaner, Simpler Capital Structure No more preferred dividend tracking or layered share classes. One equity structure = greater transparency, easier valuation, and better governance. 2️⃣ Full Financial Consolidation by FY2025 Affiliate revenues, assets, and operations will soon be merged into CSDX’s financials — giving investors a complete, integrated view of group performance and growth potential. 3️⃣ Aligned Interests Across the Group Affiliates now hold common shares, directly benefiting from CSDX’s long-term success. Everyone’s incentivized for the same outcome: sustained shareholder value. 4️⃣ Built-In Rule 144 Safeguards Converted shares aren’t being deposited at DTC and remain subject to resale restrictions — ensuring no sudden dilution or uncontrolled selling pressure. 5️⃣ Strategic Setup for 2026 and Beyond This restructuring improves access to institutional capital, uplisting prospects, and partnership opportunities — all key steps on the NASDAQ roadmap. 📊 Bottom Line: $CSDX is streamlining its foundation for transparency, credibility, and scalable growth across the global diagnostics and life sciences space. #CSDX #OTCQB #MedTech #LifeSciences #NASDAQReady otcmarkets.com/stock/CSDX/ne…

Die Umfrage wurde von Interpharm bezahlt. Wessen Brot ich ess, dessen Lied ich sing.

Gamma Interpharm Chairman wins Platinum Award at SLEOTY 2025 dailymirror.lk/business-news…

It was a pleasure hosting @FulhamFC at CS Interpharm. Exciting times ahead as we explore a powerful collaboration around @MedusaSdp. #csinterpharm #fulhamfc #Partnership #MEDUSA #HealthcareInnovation

When innovation in healthcare meets excellence in sports - great things are bound to happen. Thank you, @FulhamFC for visiting CS Interpharm, Dubai today. We’re excited about the potential partnership on @MedusaSdp and look forward to what’s coming next! $CSDX #fulhamfc #OTCQB #MEDUSA

OTC Recap: $CSDX CS Group Announces Strategic MOU Between CS Interpharm and Gulf Center Group for Customized Manufacturing Collaboration accessnewswire.com/newsroom/… #OTCRecap #Invest #Investment #Growth #MOU #Collaboration

$CSDX CS Group Announces Strategic MOU Between CS Interpharm and Gulf Center Group for Customized Manufacturing Collaboration ... accessnewswire.com/newsroom/…

#Spezialtage 07.06.2025: #TagDerApotheke (Deutschland) Der Tag der Apotheke am 7. Juni 2025 ist ein bundesweiter Aktionstag, der seit 1998 jährlich von der ABDA – Bundesvereinigung Deutscher Apothekerverbände ausgerufen wird. Ziel ist es, die vielfältigen Leistungen der Apotheken in Deutschland hervorzuheben und ihre zentrale Rolle im Gesundheitswesen zu betonen. Zudem nutzen Apothekenteams diesen Tag, um mit der Öffentlichkeit und der Politik ins Gespräch zu kommen und auf aktuelle Herausforderungen aufmerksam zu machen. 10 Dinge, die man zum Tag der Apotheke 2025 wissen sollte Datum und Ursprung Der Tag der Apotheke findet jedes Jahr am 7. Juni statt. Er wurde erstmals 1998 von der ABDA ins Leben gerufen, um die Bedeutung der Apotheken für die Arzneimittelversorgung der Bevölkerung zu unterstreichen. Ziele des Aktionstags Der Tag dient dazu, die Öffentlichkeit über das breite Leistungsspektrum der Apotheken zu informieren und die wichtige Rolle des pharmazeutischen Personals im Gesundheitswesen hervorzuheben. Aktuelle Herausforderungen Die Apothekenlandschaft in Deutschland steht vor Herausforderungen wie dem Rückgang der Apothekenzahl. So gab es Ende 2024 nur noch 17.041 Apotheken vor Ort, was die niedrigste Zahl seit 1978 darstellt. Leistungsvielfalt Apotheken bieten neben der Medikamentenabgabe zahlreiche zusätzliche Dienstleistungen an, wie Blutdruckmessungen, Impfberatungen und Medikationsanalysen. Diese Leistungen gehen über das gesetzliche Pflichtprogramm hinaus und erfordern spezielle Qualifikationen. Politische Forderungen Anlässlich des Tags der Apotheke appellieren Apothekerverbände an die Politik, die flächendeckende Arzneimittelversorgung zu sichern und Leistungskürzungen zu vermeiden. Medienkampagnen Zum Tag der Apotheke 2025 haben der Wort & Bild Verlag und gesund.de eine crossmediale Kampagne gestartet, um den Apothekenteams für ihren Einsatz zu danken. Diese umfasst TV- und Radiospots sowie Social-Media-Aktionen. Regionale Aktionen Viele Apotheken nutzen den Tag für besondere Aktionen, wie Gesundheitsberatungen, Gewinnspiele oder Informationsstände in Innenstädten, um mit der Bevölkerung in direkten Kontakt zu treten. Nachhaltigkeitsinitiativen Initiativen wie „Pharmacists for Future“ setzen sich für eine nachhaltige Pharmazie ein und nutzen den Tag der Apotheke, um auf umweltfreundliche Praktiken in Apotheken aufmerksam zu machen. Fortbildungsangebote Rund um den Tag der Apotheke finden zahlreiche Fortbildungsveranstaltungen für Apothekenteams statt, wie z.B. der ApothekenRechtTag oder die Interpharm, um aktuelle Themen und Herausforderungen zu diskutieren. Zukunftsperspektiven Der Tag der Apotheke bietet eine Plattform, um über die Zukunft der Apotheken zu diskutieren, insbesondere im Hinblick auf Digitalisierung, demografischen Wandel und die Sicherstellung der Arzneimittelversorgung in ländlichen Regionen. Der Tag der Apotheke 2025 ist somit nicht nur ein Anlass zur Wertschätzung, sondern auch ein wichtiger Impulsgeber für die Weiterentwicklung des Apothekenwesens in Deutschland.